Loading...
OTCMCYDY
Market cap269mUSD
Jan 22, Last price  
0.22USD
1D
29.35%
1Q
62.89%
Jan 2017
-67.19%
IPO
-89.53%
Name

Cytodyn Inc

Chart & Performance

D1W1MN
OTCM:CYDY chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
28.94%
Rev. gr., 5y
%
Revenues
0k
0000005,786-25,987000000000266,00000
Net income
-50m
L-37.56%
-777,083-1,489,700-2,610,070-1,193,684-1,572,804-3,736,944-3,741,137-7,492,802-9,568,301-12,431,413-25,926,713-25,703,612-25,763,801-48,458,746-56,186,660-141,783,223-174,018,000-288,163,000-79,824,000-49,841,000
CFO
-11m
L-56.26%
-694,679-602,074-935,090-473,308-1,287,005-2,146,410-1,821,417-4,391,095-3,392,933-7,386,943-12,016,858-24,810,651-26,732,468-29,897,971-50,466,164-68,803,615-117,573,000-77,723,000-25,110,000-10,982,000
Earnings
Apr 14, 2025

Profile

CytoDyn Inc. operates as a clinical-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor in the areas of human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), oncology, and such as coronavirus disease (“COVID-19”). It is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
URL
https://www.cytodyn.com/
IPO date
Nov 17, 2005
Employees
23
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑052023‑052022‑052021‑052020‑052019‑052018‑052017‑052016‑052015‑05
Income
Revenues
266
 
Cost of revenue
18,058
37,062
71,399
Unusual Expense (Income)
NOPBT
(18,058)
(37,062)
(71,133)
NOPBT Margin
Operating Taxes
12,994
77,343
Tax Rate
NOPAT
(18,058)
(50,056)
(148,476)
Net income
(49,841)
-37.56%
(79,824)
-72.30%
(288,163)
65.59%
Dividends
Dividend yield
Proceeds from repurchase of equity
9,137
25,786
41,195
BB yield
-5.97%
-11.78%
-18.96%
Debt
Debt current
29,935
34,556
36,375
Long-term debt
424
1,280
978
Deferred revenue
Other long-term liabilities
43,571
Net debt
27,249
33,295
33,122
Cash flow
Cash from operating activities
(10,982)
(25,110)
(77,723)
CAPEX
Cash from investing activities
Cash from financing activities
11,748
29,927
48,011
FCF
(71,500)
(11,179)
(83,883)
Balance
Cash
3,110
2,541
4,231
Long term investments
Excess cash
3,110
2,541
4,218
Stockholders' equity
(897,263)
(840,771)
(761,434)
Invested Capital
854,152
744,248
703,833
ROIC
ROCE
41.89%
38.40%
123.49%
EV
Common stock shares outstanding
969,509
836,528
676,900
Price
0.16
-39.72%
0.26
-18.47%
0.32
-83.11%
Market cap
152,950
-30.13%
218,919
0.75%
217,285
-80.54%
EV
180,199
252,214
254,384
EBITDA
(18,029)
(36,887)
(70,352)
EV/EBITDA
Interest
8,674
25,186
52,447
Interest/NOPBT